Testing the right tafenoquine dose for malaria prevention
Treatments studied
Part of Infections clinical trials.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have symptoms from P. vivax malaria only (no other malaria type), confirmed by a blood test
- You have a fever now or had fever within the last 7 days
- Your G6PD level is at least 70% of the typical group average (a blood test will check this)
- You are at least 2 years old and weigh over 10 kg
- You can understand the study and sign written consent (and agree to follow the plan for 4 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how the malaria medicine tafenoquine is processed in the bodies of young children with vivax malaria. It helps find the right dose for small children and ensures the treatment is safe and effective.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This Phase 3 trial tests whether giving malaria medicine to people in high-risk households (a “mass drug administration” campaign) can stop local relapses and eliminate vivax malaria. If you live close to a recent malaria case, you may be offered a preventive dose, based on age and medical safety checks.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This trial tests a combination of antimalarial drugs (tafenoquine plus artemisinin-based combination therapies) to see if it's safe and effective for treating vivax malaria. Participating may help clear the infection and prevent it from coming back.
This trial tests whether combining tafenoquine with other malaria medicines works better than a single drug for curing vivax malaria and preventing it from coming back. You would receive the study drugs and be monitored for about 6 months.
Hear when a new Plasmodium Vivax Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.